Skip to main content
. 2016 Mar;7(3-4):73–85. doi: 10.18632/genesandcancer.100

Figure 6. Underlying resistance mechanisms to letrozole and taselisib in the MCF-ARO model.

Figure 6

Drug sensitivity and cell alterations that accompany resistance are indicated.